Amgen (AMGN) – StreetInsider.com Reports
-
Wells Fargo Reiterates Overweight Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Lowered to $284 at UBS
-
Amgen (AMGN) PT Lowered to $336 at BMO Capital
-
Amgen (AMGN) PT Lowered to $271 at Morgan Stanley
-
Raymond James Resumes Amgen (AMGN) at Market Perform
-
Amgen (AMGN) PT Lowered to $331 at DZ Bank
-
Amgen (AMGN) Declares $2.25 Quarterly Dividend; 3.3% Yield
-
Goldman removes Apple stock from 'US Conviction List - Directors' Cut'
-
Goldman Makes New Monthly Adjustments to Directors Cut Names, 'inclusion on this list is not a stock rating'
-
Amgen (AMGN) PT Raised to $333 at DZ Bank
-
Amgen (AMGN) PT Raised to $322 at HSBC
-
Midday movers: Ford, Fortinet rise; Snap slumps
-
Amgen (AMGN) PT Lowered to $278 at Morgan Stanley
-
Amgen (AMGN) PT Raised to $380 at Oppenheimer
-
Leerink Partners Downgrades Amgen (AMGN) to Market Perform, 'Awaiting Obesity Results'
-
Amgen (AMGN) PT Raised to $329 at RBC Capital
-
Amgen (AMGN) PT Raised to $215 at Baird
-
Amgen (AMGN) PT Raised to $350 at Goldman Sachs
-
Amgen (AMGN) Q4 earnings and revenue beat estimates
-
Amgen quarterly profit rises 15%, obesity drug trials are on track
-
Amgen (AMGN) Tops Q4 EPS by 12c, Offers Guidance
-
Amgen (AMGN) Tops Q4 EPS by 12c; offers guidance
-
Amgen (AMGN) option IV elevated into quarter results and new treatment outlook
-
Eli Lilly earnings ahead, Toyota lifts annual guidance - what's moving markets
-
Amgen (AMGN) February weekly 322 straddle into quarter results
-
Amgen (AMGN) February weekly option implied volatility into quarter results
-
Dow Jones, Nasdaq, S&P 500 weekly preview: Earnings season continues
-
Amgen (AMGN) February weekly 322 straddle priced into quarter results
-
Amgen (AMGN) PT Raised to $375 at Jefferies
-
Amgen (AMGN) PT Raised to $285 at Deutsche Bank
-
Amgen (AMGN) PT Lowered to $314 at UBS
-
Amgen (AMGN) PT Raised to $290 at JPMorgan
-
Midday movers: Apple, Tesla, Eli Lilly and more
-
Amgen (AMGN) PT Raised to $345 at Jefferies
-
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.07%
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.30%
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43%
-
Amgen (AMGN) Receives CRL for LUMAKRAS NDA
-
Daiwa Securities Upgrades Amgen (AMGN) to Buy (1)
-
Amgen (AMGN) lifted at BMO Capital as analysts see 22% potential upside
-
BMO Capital Upgrades Amgen (AMGN) to Outperform
-
Amgen (AMGN) Announces Executive Appointments To Accelerate Innovation
-
Jefferies discusses potential GLP1/obesity buyers and M&A targets
-
Amgen (AMGN) Announces FDA Grants Priority Review to Tarlatamab Application for Advanced Small Cell Lung Cancer
-
Amgen (AMGN) Raises Quarterly Dividend 5.6% to $2.25; 3.3% Yield
-
RBC Capital upgrades Amgen (AMGN) on 'improving position of stability' and diminishing uncertainty
-
RBC Capital Upgrades Amgen (AMGN) to Outperform; 'Diversification, Pipeline Optionality & 2024 Catalysts'
-
Ideaya Biosciences (IDYA) Mentioned Positively at Citi, 'developing into an attractive takeout candidate'
-
Amazon (AMZN) AWS Joins Forces With Amgen on Generative AI Solutions to Accelerate Advanced Therapies
-
TD Cowen Starts Harpoon Therapeutics (HARP) at Outperform
Back to AMGN Stock Lookup